AHA 2005

Withholding Abciximab Infusion After Stenting

Olivier Bertrand
Olivier Bertrand

The use of abciximab perfusion after stenting was questioned at the American Heart Association meeting in Dallas. The EASY study found bolus administration of glycoprotein 2B3A inhibition was sufficient and gives the possibility of sending patients home early.Olivier Bertrand, Hôpital Laval, Quebec.

Click here for all the interviews from AHA 2005

Similar Interviews

  • Audio Journal of Cardiovascular Medicine 12.1, January 2006
  • Reporting from: American Heart Association Annual Scientific Sessions November 13-16, 2005, Dallas In this edition: Bryan Williams told American Heart Association attendees that

  • Audio Journal of Cardiovascular Medicine 12.1, January 2006
  • Reporting from: American Heart Association Annual Scientific Sessions November 13-16, 2005, Dallas Scientific Editors: Michael Petch, Papworth Hospital, Cambridge Man Fai Shiu, Walsgrave Hospital,

  • Eptifibatide as Effective as Abciximab in Primary PCI for Acute ST Elevation Myocardial Infarction: EVA-AMI Study
  • Uwe Zeymer REFERENCE: Late Breaking Clinical Trials Session I, American Heart Association Scientific Sessions, 4-7 November, 2007,

    Post a comment

    Subscribe to Audio Medica Podcast